Alphamab Oncology (HK:9966) has released an update.
Alphamab Oncology has announced at the ESMO Congress 2024 that their experimental drug JSKN003 shows promise in treating patients with advanced solid tumors, particularly those heavily pretreated for PROC (platinum-resistant ovarian cancer). The medication, which targets HER2, has been associated with significant tumor shrinkage and presented a favorable safety profile, suggesting further clinical evaluation is warranted.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.
